Navigation Links
Cell Genesys Reports GVAX Immunotherapy for Prostate Cancer Induces,a Broad, Patient-Specific Antibody Response

80 patients with metastatic hormone-refractory prostate cancer (HRPC). Additional follow-up of the 22 patients who received the dose that is comparable to that being employed in the company's ongoing Phase 3 program revealed that their median survival is 35.0 months. Four patients have withdrawn consent to further follow-up and thus were censored in the analysis. The company also has previously reported final median survival results from its first multi-center Phase 2 trial of GVAX immunotherapy for prostate cancer in 34 patients with metastatic HRPC that showed an overall median survival of 26.2 months. The survival results from the two, independent multi-center Phase 2 clinical trials compare favorably to the previously published median survival of 18.9 months for metastatic hormone-refractory prostate cancer patients treated with Taxotere(R) (docetaxel) chemotherapy plus prednisone, the current standard of care for these patients. The company's ongoing Phase 3 program is designed to confirm this potential survival benefit of GVAX immunotherapy for prostate cancer.

"The immune response data reported today provide added support for the concept that a whole-cell immunotherapy, such as GVAX immunotherapy for prostate cancer, is an ideal multi-antigen source that is capable of eliciting an immune response to a broad array of tumor-associated antigens," stated Peter K. Working, Ph.D., senior vice president of Research and Development at Cell Genesys. "That the majority of antibody responses are unique to individual patients is further evidence that the non patient-specific format of GVAX immunotherapies is capable of inducing unique, patient-specific immune responses. Moreover, the fact that many of these antigens have not before been associated with prostate cancer, further suggests that a multivalent antigen immunotherapy like GVAX immunotherapy may provide the best potential for inducing an effective anti-tumor immune response, especially for heterogeneous ca
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
2. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
3. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
4. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
5. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
8. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
(Date:8/31/2015)... 2015 Regen BioPharma, Inc. (OTCBB: RGBP) ... novel means of delivering its patented (US Patent ... tumors utilizing a clinically approved formulation as delivery ... with gene silencing therapeutics in which the gene ... whole body.  By utilizing a local delivery system, ...
(Date:8/31/2015)... and MOUNTAIN VIEW, Calif. , Aug. ... ; EURONEXT: SAN) and the life sciences team at ... care and outcomes for people with type 1 and ... treatments and devices with Google,s expertise in analytics, miniaturized ... explore how to improve diabetes care by developing new ...
(Date:8/31/2015)...  Qualcomm Incorporated (NASDAQ: QCOM ) today ... is collaborating with Davita Healthcare Partners and ... by Qualcomm Life,s 2net™ Device Connectivity Platform and ... informed interventions and better management of at-risk populations. ... Connect 2015 ecosystem conference taking place ...
Breaking Medicine Technology:Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 2Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 3Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 2Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 3Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 4Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 5Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 6Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 2Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 3Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 4Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 5
... 7, 2011  Tethys Bioscience has entered into an agreement ... employers measurably flatten the trajectory of their healthcare trends ... their employee populations. The agreement allows ACAP Health to ... as a component of its disease intervention programs. The ...
... 2011 Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE ... and develops new uses for previously approved drugs and ... of the granting of a European patent with broad ... diketopiperazine which is the active ingredient of Ampion™.  The ...
Cached Medicine Technology:Tethys Bioscience and ACAP Health Consulting Partner to Help Employers Prevent Diabetes 2Tethys Bioscience and ACAP Health Consulting Partner to Help Employers Prevent Diabetes 3Ampio Pharmaceuticals Awarded European Patent that Strengthens Intellectual Property Protection for its key drug Ampion™ 2
(Date:9/1/2015)... ... September 01, 2015 , ... Elizabeth Callahan, MD, founder and medical director of ... area to offer RADIESSE® filler treatment for volume loss in the hands. RADIESSE provides ... veins in the hands, delivering smooth, natural-looking results that can last up to one ...
(Date:9/1/2015)... ... September 01, 2015 , ... MediNatura™, the exclusive U.S. importer ... physician assistants (PAs) practicing in orthopedics. The workshop, titled “Treatment of Osteoarthritis Knee ... Erick Salado, an orthopedic surgeon at South Florida Bone and Joint Institute, Inc. ...
(Date:9/1/2015)... ... September 01, 2015 , ... Curly ... professional hair salons. This highly anticipated partnership between Curly Hair Solutions™ and Trade ... Collection. Founder Jonathan Torch and the Curly Hair Solutions™ team could not be ...
(Date:8/31/2015)... ... August 31, 2015 , ... Jvion, ... their latest predictive use case focused on helping hospital perform under the Center ... program, hospital payments are adjusted based on performance across four domains related to ...
(Date:8/31/2015)... , ... August 31, 2015 , ... ... Institute (WDI) at Western University of Health Sciences to learn more about its ... Periodontology, School of Dental Sciences and Institute of Cellular Medicine at Newcastle University, ...
Breaking Medicine News(10 mins):Health News:SkinSmart Dermatology in Sarasota is Now Offering RADIESSE to Rejuvenate Hands 2Health News:SkinSmart Dermatology in Sarasota is Now Offering RADIESSE to Rejuvenate Hands 3Health News:New Hope for Patients Seeking Treatment of Osteoarthritis Knee Pain 2Health News:New Hope for Patients Seeking Treatment of Osteoarthritis Knee Pain 3Health News:Curly Hair Solutions™ Partners With Trade Secrets 2Health News:Jvion Releases Value-Based Purchasing Predictive Use Case 2Health News:Western Diabetes Institute Collaborates with UK team 2Health News:Western Diabetes Institute Collaborates with UK team 3Health News:Western Diabetes Institute Collaborates with UK team 4
... potential to alter voice characteristics. One solution for sleep apnoea ... night - is to remodel the nasal and throat cavity ... a flap of tissue at the top of the throat ... - in an operation called uvulopalatopharyngoplasty (UPPP) - the shape ...
... sense of humour has nothing to do with your genes, and ... traits such as being introverted or extroverted are believed to be ... applied to our sense of humour. ,The team asked 71 ... go into separate rooms and rate five cartoons on a scale ...
... Healthy, hearing babies born to deaf parents and exposed ... ``babble,'' indicating that babbling serves as an important precursor ... a professor in the departments of Psychological & Brain ... Hampshire believes, that this must be the key that ...
... new bacterial genome sequence suggests a route to new ... evade antibiotics, even minor infections can become a major ... to tackle resistant bacteria.// ,Antibiotic resistance is a ... antibiotics come from the soil bacteria Streptomyces , including ...
... According to a research obese heart patients live on ... overweight also hastens the onset of heart disease by ... stay slim. ,It has long been known ... from Duke University Medical Center, North Carolina, have become ...
... released by the Institute for the Study of Aging and ... stay mentally agile are better advised to put down the ... shows that seniors who do crossword puzzles, exercise and seek ... who put their trust in unproven cures such as melatonin, ...
Cached Medicine News:
Hemagglutination slide test for the qualitative and quantitative detection of Rheumatoid Factor in serum or synovial fluid....
Hemagglutination slide test for the differential qualitative detection and quantitative determination of infectious mononucleosis and other heterophile antibodies in serum or plasma....
Color-enhanced hemagglutination slide test for the rapid qualitative and semi-quantitative detection of infectious mononucleosis heterophile antibodies in serum or plasma....
... Inverness Medical Professional Diagnostics is a leading ... IFA and DFA test menu that includes ... STDs as well as miscellaneous conjugates and ... you a wide assortment of substrates and ...
Medicine Products: